LydiaRx exists so that countries can build population genomics programmes they own. Secure. In-country. Governed by their own people. Built for the populations they serve.
Genomic medicine has been built on a narrow slice of humanity. The reference data that shapes drug development, dosing and disease-risk models comes overwhelmingly from populations of European ancestry. The populations with the most decisive biology (large, consanguineous, genetically distinct) are the least represented. The countries that hold them have too often been offered a poor choice. Export the data to someone else's cloud, or do nothing.
We founded LydiaRx to give governments a third option. We build the sovereign data layer for national genome programmes, and the evidence layer that turns population genomics and regulatory data into decision-grade, provenance-backed knowledge. We are a small core team by design: we hold the mandate, the legal architecture, the supply chain and the governance; national institutions collect, sequence and analyse, and the country owns the result. Headquartered in the United Kingdom, with a local operating presence formed in each programme country.
So we take no ownership of samples or data, ever. The State owns; a public institution holds; a national-majority committee decides.
So we built a platform where researchers bring their questions to the data. They leave with answers, never with copies.
So we run the environment under the same controls as every partner, on a ledger the State verifies without our help.
So we design every programme so that governed research access funds the centre after the pilot and returns a share to the State.
So we finance the first step privately, publish every governance document, and submit to two independent audits.
So we name our people and our company number. We invite you to verify both.
An AI-strategy engagement for a clinical-stage cardiometabolic company.
Dr Shahid Hanif, formerly Head of Health Data and Outcomes at the ABPI, joins as adviser.
One million whole genomes over four phases, delivered in-country and owned by the State.
Programme architecture and financing structure built. The independent Governance and Ethics Board convened under Dr Andrew Roddam, with Pakistan-resident clinical and academic co-leads.
Project agreements and the data-sovereignty and licence framework drafted and in negotiation. The Sovereignty and Trust Charter written.
United States provisional patent applications filed for Atlas, Prism and Phylax. Term sheet agreed for the locally majority-owned national joint venture.
Proposal finalised: 400 whole genomes and the first Pakistani pangenome. Ready for ethics submission.
Advisers from the 100,000 Genomes Project, Genomics England and Oxford translational research join. Programmes proposed or in discussion in six countries across South Asia, the Gulf, the Indian Ocean, Türkiye, the Balkans and Southern Africa.
We are a small team. A briefing is with a founder.